Serum BDNF levels in patients with opioid dependence during the early withdrawal period: A case control study

Publication date: 10 August 2018
Source:Neuroscience Letters, Volume 681
Author(s): Siddharth Sarkar, Raka Jain, Shanti M. Kethawath, Rishi Gupta, Mukesh Kumar
Background and aimsBrain-Derived Neurotrophic Factor (BDNF), a neuropeptide important for neural growth and differentiation has been explored in patients with opioid dependence. We aimed to compare the serum BDNF levels in patients with opioid dependence with age and gender matched controls, and to assess change in BDNF levels during initial withdrawal period.MethodsThirty cases with a diagnosis of opioid dependence were compared to forty healthy controls. BDNF levels were measured at inclusion for all participants. Additionally, BDNF levels were measured in patients with opioid dependence after 10 days of inpatient detoxification.ResultsThere were no group differences in BDNF levels between cases and controls for day 1 BDNF levels. Also, there was no significant difference observed in the BDNF levels in patients at day 1 and 10 of inpatient detoxification. BDNF levels did not correlate with severity of nicotine dependence, age of the cases or duration of opioid dependence.ConclusionThe results from the study provide further insights into the relationship of BDNF levels and opioid dependence.

Graphical abstract

image